Literature DB >> 22251932

Polysomnographic measures of disturbed sleep are associated with reduced quality of life in multiple sclerosis.

Daria A Trojan1, Marta Kaminska, Amit Bar-Or, Andrea Benedetti, Yves Lapierre, Deborah Da Costa, Ann Robinson, Mauro Cardoso, Kevin Schwartzman, R John Kimoff.   

Abstract

BACKGROUND: The relationship of objective sleep parameters with health-related quality of life (HRQoL) in multiple sclerosis (MS) has not been studied.
OBJECTIVE: To evaluate the relationship between polysomnographic (PSG) parameters and HRQoL in MS.
METHODS: Ambulatory MS patients without a known sleep disorder completed the Short Form (36) Health Survey (SF-36), pain visual analog scale, and two consecutive overnight PSGs. HRQoL was assessed using SF-36 Physical and Mental Component Summary (PCS, MCS) scores. Standard objective PSG measures of sleep quality were determined. The relationship between objective sleep parameters and HRQoL was evaluated with multivariate linear regression, adjusting for age, sex, body mass index, disability, and pain.
RESULTS: 62 MS patients were included. PSG measures of sleep disruption including stage changes, awakenings, time in N1 sleep, and apnea-hypopnea and total arousal indices were negatively associated (p<0.05) with MCS scores (lower scores indicating poorer HRQoL). PSG parameters reflective of better sleep quality including total sleep time, sleep efficiency, and time in REM sleep were positively associated with MCS scores. PSG parameters were not significantly associated with PCS scores.
CONCLUSIONS: PSG-documented sleep disruption negatively impacts, while better objective sleep quality positively impacts on the mental domain of HRQoL in MS.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22251932     DOI: 10.1016/j.jns.2011.12.013

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

Review 1.  Sleep Disorders in Multiple Sclerosis.

Authors:  Tiffany J Braley; Eilis Ann Boudreau
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

Review 2.  A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis.

Authors:  Tiffany J Braley; Ronald D Chervin
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

3.  Leg movement activity during sleep in multiple sclerosis with and without restless legs syndrome.

Authors:  Raffaele Ferri; Davide Sparasci; Anna Castelnovo; Silvia Miano; Kosuke Tanioka; Naoko Tachibana; Chiara Carelli; Gianna Carla Riccitelli; Giulio Disanto; Chiara Zecca; Claudio Gobbi; Mauro Manconi
Journal:  J Clin Sleep Med       Date:  2022-01-01       Impact factor: 4.062

4.  Poor sleep in patients with multiple sclerosis.

Authors:  Hanne Marie Bøe Lunde; Tommy F Aae; William Indrevåg; Jan Aarseth; Bjørn Bjorvatn; Kjell-Morten Myhr; Lars Bø
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

5.  Sleep Disorders Reduce Health-Related Quality of Life in Multiple Sclerosis (Nottingham Health Profile Data in Patients with Multiple Sclerosis).

Authors:  Christian Veauthier; Gunnar Gaede; Helena Radbruch; Klaus-Dieter Wernecke; Friedemann Paul
Journal:  Int J Mol Sci       Date:  2015-07-21       Impact factor: 5.923

6.  Sleep abnormality in neuromyelitis optica spectrum disorder.

Authors:  Yijun Song; Liping Pan; Ying Fu; Na Sun; Yu-Jing Li; Hao Cai; Lei Su; Yi Shen; Linyang Cui; Fu-Dong Shi
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-04-16

7.  Health self-assessment by hemodialysis patients in the Brazilian Unified Health System.

Authors:  Tiago Ricardo Moreira; Luana Giatti; Cibele Comini Cesar; Eli Iola Gurgel Andrade; Francisco de Assis Acurcio; Mariângela Leal Cherchiglia
Journal:  Rev Saude Publica       Date:  2016-05-03       Impact factor: 2.106

8.  Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).

Authors:  Sulaiman Khadadah; R John Kimoff; Pierre Duquette; Vincent Jobin; Yves Lapierre; Andrea Benedetti; Fatema T Johara; Ann Robinson; Elaine Roger; Amit Bar-Or; Gabriel Leonard; Marta Kaminska; Daria A Trojan
Journal:  Mult Scler       Date:  2021-04-23       Impact factor: 6.312

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.